AFC-HD AMS Life Science Co., Ltd.
2927.T · JPX
11/30/2025 | 8/31/2025 | 5/31/2025 | 2/28/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.90 | 0.22 | -0.83 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 22.04 | 50.58 | 21.79 | 22.37 |
| Quality | ||||
| ROIC | 1.25% | -0.04% | 1.00% | 1.07% |
| Gross Margin | 34.68% | 34.03% | 34.10% | 32.77% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 7.36% | 8.48% | 9.23% | 9.97% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 11.42 | 26.17 | 11.28 | 11.54 |
| Interest Coverage | 14.29 | 9.52 | 9.69 | 13.53 |
| Efficiency | ||||
| Inventory Turnover | 0.81 | 0.74 | 0.72 | 0.86 |
| Cash Conversion Cycle | 88.24 | 91.86 | 98.13 | 79.23 |